<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="672">
  <stage>Registered</stage>
  <submitdate>13/09/2005</submitdate>
  <approvaldate>9/05/2006</approvaldate>
  <actrnumber>ACTRN12606000163505</actrnumber>
  <trial_identification>
    <studytitle>ATTAX</studytitle>
    <scientifictitle>ATTAX: A randomised phase II study evaluating tumour response rates of a weekly schedule of docetaxel with cisplatin and 5-FU (wTCF) or with Capecitabine (wTX) in advanced oesophago-gastric cancer.</scientifictitle>
    <utrn />
    <trialacronym>ATTAX</trialacronym>
    <secondaryid>Australasian Gastro-Intestinal Trials Group: AG0603G</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Locally recurrent or metastatic oesophago-gastric cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Oesophageal (gullet)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Stomach</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This study has two treatment arms: 
Weekly TCF consisting of Docetaxel 30 mg/m2 d1, d8; Cisplatin 60 mg/m2 d1 and protracted venous infusion fluorouracil (5-FU) 200 mg/m2/d for 21d
Weekly TX consisting of Docetaxel 30 mg/m2 d1, d8; Capecitabine 800 mg/m2 bd orally d1-14.
Each cycle administered 3 weekly for a total of 8 cycles.</interventions>
    <comparator>This study has two treatment arms, which are not compared, therefore there is no comparator/control.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To evaluate tumour response rates of weekly docetaxel, cisplatin and 5-FU or weekly docetaxel and capecitabine in the treatment of patients with metastatic or locally recurrent oesophago-gastric cancer. Treatment will continue for 24 weeks and tumour response will be assessed according to Response Evaluation Criteria in Solid Tumours (RECIST) guidelines.</outcome>
      <timepoint>Assessed every 6 weeks.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To assess comparative overall survival, progression-free survival, treatment related toxicity, disease associated symptoms and quality of life using treatment with weekly docetaxel, cisplatin and 5-FU or weekly docetaxel and capecitabine. </outcome>
      <timepoint>Overall survival will be measured from date of patient entry onto the study to date of death from any cause. At completion of protocol treatment patients will be followed up every 12 weeks until disease progression.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria> Histological diagnosis of metastatic or locally recurrent oesophago-gastric cancer (squamous cell, adenocarcinoma or undifferentiated carcinoma)-Any primary oesophago-gastric site (oesophagus, oesophago-gastric junction (OGJ) or stomach)-Unidimensional measurable disease as assessed by CT scan (RECIST criteria)- No prior radiation except for; Adjuvant radiation (radiation alone or chemo-radiation allowed) which must have been completed &gt;12 months ago.  For patients who have received adjuvant radiotherapy, the site(s) of measurable disease should include at least one which was not encompassed by the radiation field(s) unless this site has demonstrated clear progression.Palliative radiotherapy provided there was no concurrent chemotherapy administered, all radiation toxicities have resolved to grade 1 or less and at least 14d has elapsed from the last dose of radiotherapy until the start of chemotherapy in ATTAX.  For patients who have received palliative radiotherapy, the site(s) of measurable disease should include at least one which was not encompassed by the radiation field(s)-No prior chemotherapy agents, except adjuvant chemotherapy &gt; 12 months ago.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Metastatic disease of the central nervous system.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by fax</concealment>
    <sequence>Stratified urn model with stratification by Site and Eastern Conference Oncology Group (ECOG) status. Randomisation lists were generated by computer and the randomisation process was done manually.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>2/06/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Australasian Gastro-Intestinal Trials Group A(AGITG)</primarysponsorname>
    <primarysponsoraddress>92-94 Parramatta Road, Camperdown, NSW, 2050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Educational Grant from Sanofi-Aventis</fundingname>
      <fundingaddress>12-24 Talavera Road, Macquarie Park NSW 2113</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>NHMRC Clinical Trials Centre, University of Sydney</sponsorname>
      <sponsoraddress>92-94 Parramatta Road, Camperdown, NSW, 2050</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Most cases of oesophageal and gastric cancer are locally advanced or metastatic at presentation.  Chemotherapy prolongs survival and improves quality of life in such patients, but standard chemotherapy for this disease has not been defined. 
Doxetaxel is a taxane with promising single agent activity in oesophago-gastric cancer. Combination chemotherapy regimens based on docetaxel may therefore have significant activity with a more favourable toxicity profile.
This randomised phase II study explores the activity and toxicity of two novel docetaxel based regimens; weekly docetaxel, cisplatin and infused 5-FU (wTCF) and weekly docetaxel plus capecitabine (wTX) in patients with metastatic oesophago-gastric cancer.  Based on the results achieved in this study, the AGITG would aim to test the best regimen in a future phase III study comparing it with ECF or another accepted standard regimen.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal North Shore Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>24/05/2005</ethicapprovaldate>
      <hrec> AG0603G</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead</ethicname>
      <ethicaddress />
      <ethicapprovaldate>15/03/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Nepean Cancer Care Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate>22/11/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Prince of Wales Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>2/12/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Saint Vincent's Hospital Darlinghurst</ethicname>
      <ethicaddress />
      <ethicapprovaldate>14/10/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Condord</ethicname>
      <ethicaddress />
      <ethicapprovaldate>18/07/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Campelltown-Liverpool Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>27/09/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Bankstown-Lidcombe Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>26/07/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Newcastle Mater Misericordia Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>22/09/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate>7/09/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Saint Vincent's Hospital Melbourne</ethicname>
      <ethicaddress />
      <ethicapprovaldate>15/10/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Frankston Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>19/10/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Austin Health</ethicname>
      <ethicaddress />
      <ethicapprovaldate>18/05/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Monash Medical Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate>20/12/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Border Medical Oncology</ethicname>
      <ethicaddress />
      <ethicapprovaldate>16/06/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Princess Alexandra Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>6/07/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Queen Elizabeth Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>17/05/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>23/06/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Perth Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>3/08/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Fremantle Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>27/09/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Hobart</ethicname>
      <ethicaddress />
      <ethicapprovaldate>16/03/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Christchurch</ethicname>
      <ethicaddress />
      <ethicapprovaldate>22/06/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Niall Tebbutt</name>
      <address>Department of Medical Oncology
Austin Hospital
Studley Road
Heidelberg VIC 3084</address>
      <phone>+61 3 94963217</phone>
      <fax>+61 3 94576698</fax>
      <email>niall.tebbutt@ludwig.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Burcu Cakir</name>
      <address>National Health and Medical Research Council (NHMRC) Clinical Trials Centre
Locked Bag 77
Camperdown NSW 1450</address>
      <phone>+61 2 95625000</phone>
      <fax>+61 2 95625094</fax>
      <email>Burcu.Cakir@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Michelle Cummins</name>
      <address>National Health and Medical Research Council (NHMRC) Clinical Trials Centre Locked Bag 77 Camperdown NSW 1450</address>
      <phone>+61 2 95625000</phone>
      <fax>+61 2 95625094</fax>
      <email>michelle.cummins@sydney.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>